WHAT IS CLAIMED IS:

1. A compound represented by Formula I



I

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

n is 0, 1 or 2;

J is selected from NR^1 or $C(R^1)(R^2)$;

K is selected from NR^3 or $C(R^3)(R^4)$;

L is selected from NR^5 or $C(R^5)(R^6)$;

X is a bond, -C(O), $-N(R^{14})-$, $-N(R^{14})-C(O)-$, or  ;

R^1, R^8 and R^{10} are each independently selected from the group consisting of:

(1) C_{1-6}alkyl,
(2) C_{2-6}alkenyl,
(3) C_{3-6}akynyl,
(4) C_{3-6}cycloalkyl,
(5) C_{1-6}alkoxy,
(6) C_{1-6}alkyl-$S(O)_k$-, wherein k is 0, 1 or 2,
(7) aryl,
(8) aralkyl,

(9) HET,
(10) -C_{1-6}alkyl-HET,
(11) aryloxy,
(12) aroyloxy,
(13) aralkenyl,
(14) aralkynyl,
(15) hydrogen,
(16) hydroxy and
(17) C_{1-6}alkyl-N(R^{14})-S(O)$_k$-, wherein k is 0, 1 or 2,

wherein items (1) to (6) above and the alkyl portions of items (8), (10) and (17) above and the alkenyl portion of item (13) above and the alkynyl portion of item (14) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13}, N(R^{14})$_2$, C_{3-6}cycloalkyl, C_{1-6}alkyl-S(O)$_k$- and aryl-S(O)$_k$-, wherein k is 0, 1 or 2, and

wherein items (7), (9), (11) and (12) above and aryl portion of items (8), (13) and (14) above and the HET portion of item (10) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:

(a) halo,
(b) OR^{13},
(c) N(R^{14})$_2$,
(d) C_{1-6}alkyl,
(e) C_{2-6}alkenyl,
(f) C_{3-6}akynyl,
(g) C_{1-6}alkyl-S(O)$_k$-, wherein k is 0, 1 or 2,
(h) aryl,
(i) aryl-S(O)$_k$-, wherein k is 0, 1 or 2,
(j) HET,
(k) aralkyl,
(l) aroyl,
(m) aryloxy,
(n) aralkoxy and

(o) CN,

wherein items (d) to (g) above and the alkyl portions of item (k) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13} and $N(R^{14})_2$, and

wherein items (h), (i), (j), (l) and (m) above and the aryl portions of items (k) and (n) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13} and C_{1-4}alkyl,

or when X is a bond then R^8 and R^{10} may be joined together to form a 4- to 8-membered monocylic ring, optionally containing 1-3 heteroatoms selected from O, S and NR^{14}, and optionally containing 1 or 2 double bonds;

R^2, R^3, R^4, R^5 and R^6 are each independently selected from the group consisting of:

(1) hydrogen,
(2) halo,
(3) C_{1-6}alkyl,
(4) C_{2-6}alkenyl,
(5) C_{3-6}akynyl,
(6) C_{3-6}cycloalkyl,
(7) C_{1-6}alkoxy,
(8) C_{1-6}alkyl-$S(O)_k$-, wherein k is 0, 1 or 2,
(9) aryl,
(10) aralkyl,
(11) HET and
(12) -C_{1-6}alkyl-HET,

wherein items (3) to (8) above and the alkyl portions of items (10) and (12) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13}, $N(R^{14})_2$ and C_{1-6}alkyl-$S(O)_k$-, wherein k is 0, 1 or 2; and

wherein items (9) and (11) and the aryl portion of items (10) and the HET portion of item (12) are optionally substituted from one up to the maximum number of substituable positions with a substituent independently selected from the group consisting of:

(a) halo,
(b) OR^{13},
(c) $N(R^{14})_2$,
(d) C_{1-6}alkyl,
(e) C_{2-6}alkenyl,
(f) C_{3-6}akynyl and
(g) C_{1-6}alkyl-$S(O)_k$-, wherein k is 0, 1 or 2,

wherein items (d) to (g) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13} and $N(R^{14})_2$,

or R^1 and R^3 or R^3 and R^5 may be joined together to form a double bond;

R^7 is selected from the group consisting of:

(1) hydrogen,
(2) OR^{13},
(3) C_{1-4}alkyl,
(4) aryl and
(5) aralkyl,

wherein item (3) above and the alkyl portion of item (5) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13} and $N(R^{14})_2$, and

wherein item (4) above and the aryl portion of item (5) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:

(a) halo,
(b) OR^{13},
(c) $N(R^{14})_2$,

(d) C_{1-6}alkyl,
(e) C_{2-6}alkenyl and
(f) C_{3-6}akynyl,

wherein items (d) to (f) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13} and $N(R^{14})_2$;

Y is selected from the group consisting of:

(1) hydrogen,
(2) $-O-R^9$,
(3) $-S(O)_k-R^9$, wherein k is 0, 1 or 2,
(4) $-C-W-R^9$, wherein W is O or $S(O)_k$,
(5) $-N(R^{15})2$,
(6) $-S(O)_k-N(R^{15})_2$,
(7) $-N(R^{15})-S(O)k-N(R^{15})_2$,
(8) NO_2,
(9) $-C(O)-R^{15}$,
(10) $-C(O)O-R^{15}$,
(11) -CN,
(12) halo and
(13) $-O-S(O)_k-R^{15}$,

R^9 is selected from the group consisting of: hydrogen, C_{1-12}alkyl and aryl, wherein C_{1-12}alkyl and aryl are optionally substituted from one up to the maximum number of substituents with halo, or when Y is OR^9 then R^8 and R^9 may be joined together to form a carbonyl group;

each R^{11} and R^{12} is independently selected from the group consisting of:

(1) halo,
(2) C_{1-6}alkyl,
(3) C_{2-6}alkenyl,
(4) C_{1-6}alkoxy and
(5) hydroxy,

wherein items (2) to (4) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{12}, $N(R^{13})_2$ and C_{1-6}alkyl-$S(O)_k$-, wherein k is 0, 1 or 2;

each R^{13} and R^{14} is independently selected from the group consisting of hydrogen, C_{1-4}alkyl and C_{2-4}alkenyl, each of said C_{1-4}alkyl and C_{2-4}alkenyl optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, C_{1-4}alkoxy, aryl, C_{3-6}cycloalkyl, CN and C_{1-4}alkyl-$S(O)_k$, wherein k is 0, 1 or 2;

each R^{15} is independently selected from the group consisting of: hydrogen, C_{1-6}alkyl, aryl and C_{1-12}alkoxycarbonyl, wherein said C_{1-6}alkyl and C_{1-12}alkoxycarbonyl are optionally substituted from one up to the maximum number of substituable positions with halo and said aryl is optionally substituted from one up to the maximum number of substituable positions with halo and C_{1-4}alkyl, optionally substituted with 1-3 halo groups; and

HET is a 5- to 10-membered aromatic, partially aromatic or non-aromatic mono- or bicyclic ring, containing 1-4 heteroatoms selected from O, S and N, and optionally substituted with 1-2 oxo groups.

2. A compound according to Claim 1 represented by Formula I



I

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

n is 0, 1 or 2;

J is selected from NR^1 or $C(R^1)(R^2)$;

K is selected from NR^3 or $C(R^3)(R^4)$;

L is selected from NR^5 or $C(R^5)(R^6)$;

X is a bond, -C(O), $-N(R^{14})-$, $-N(R^{14})-C(O)-$, or  ;

R^1, R^8 and R^{10} are each independently selected from the group consisting of:

(1) C_{1-6}alkyl,
(2) C_{2-6}alkenyl,
(3) C_{3-6}akynyl,
(4) C_{3-6}cycloalkyl,
(5) C_{1-6}alkoxy,
(6) C_{1-6}alkyl-$S(O)_k$-, wherein k is 0, 1 or 2,
(7) aryl,
(8) aralkyl,
(9) HET,
(10) -C_{1-6}alkyl-HET,
(11) aryloxy,
(12) aroyloxy,
(13) aralkenyl,
(14) aralkynyl,
(15) hydrogen,
(16) hydroxy and
(17) C_{1-6}alkyl-$N(R^{14})-S(O)_k$-, wherein k is 0, 1 or 2,

wherein items (1) to (6) above and the alkyl portions of items (8), (10) and (17) above and the alkenyl portion of item (13) above and the alkynyl portion of item (14) above are optionally substituted from one up to the maximum number of substitutable

positions with a substituent independently selected from the group consisting of: halo, OR^{13}, $N(R^{14})_2$, C_{3-6}cycloalkyl and C_{1-6}alkyl-$S(O)_k$-, wherein k is 0, 1 or 2, and

wherein items (7), (9), (11) and (12) above and aryl portion of items (8), (13) and (14) above and the HET portion of item (10) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:

(a) halo,
(b) OR^{13},
(c) $N(R^{14})_2$,
(d) C_{1-6}alkyl,
(e) C_{2-6}alkenyl,
(f) C_{3-6}akynyl,
(g) C_{1-6}alkyl-$S(O)_k$-, wherein k is 0, 1 or 2,
(h) aryl,
(i) aryl-$S(O)_k$-, wherein k is 0, 1 or 2,
(j) HET,
(k) aralkyl,
(l) aroyl,
(m) aryloxy,
(n) aralkoxy and
(o) CN,

wherein items (d) to (g) above and the alkyl portions of item (k) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13} and $N(R^{14})_2$, and

wherein items (h), (i), (j), (l) and (m) above and the aryl portions of items (k) and (n) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13} and C_{1-4}alkyl,

or when X is a bond then R^8 and R^{10} may be joined together to form a 4- to 8-membered monocylic ring, optionally containing 1-3 heteroatoms selected from O, S and NR^{14}, and optionally containing 1 or 2 double bonds;

R^2, R^3, R^4, R^5 and R^6 are each independently selected from the group consisting of:

(1) hydrogen,
(2) halo,
(3) C_{1-6}alkyl,
(4) C_{2-6}alkenyl,
(5) C_{3-6}akynyl,
(6) C_{3-6}cycloalkyl,
(7) C_{1-6}alkoxy,
(8) C_{1-6}alkyl-$S(O)_k$-, wherein k is 0, 1 or 2,
(9) aryl,
(10) aralkyl,
(11) HET and
(12) -C_{1-6}alkyl-HET,

wherein items (3) to (8) above and the alkyl portions of items (10) and (12) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13}, $N(R^{14})_2$ and C_{1-6}alkyl-$S(O)_k$-, wherein k is 0, 1 or 2; and

wherein items (9) and (11) and the aryl portion of items (10) and the HET portion of item (12) are optionally substituted from one up to the maximum number of substituable positions with a substituent independently selected from the group consisting of:

(a) halo,
(b) OR^{13},
(c) $N(R^{14})_2$,
(d) C_{1-6}alkyl,
(e) C_{2-6}alkenyl,
(f) C_{3-6}akynyl and
(g) C_{1-6}alkyl-$S(O)_k$-, wherein k is 0, 1 or 2,

wherein items (d) to (g) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13} and $N(R^{14})_2$,

or R^1 and R^3 or R^3 and R^5 may be joined together to form a double bond;

R^7 is selected from the group consisting of:

(1) hydrogen,
(2) OR^{13},
(3) C_{1-4}alkyl,
(4) aryl and
(5) aralkyl,

wherein item (3) above and the alkyl portion of item (5) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13} and $N(R^{14})_2$, and

wherein item (4) above and the aryl portion of item (5) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:

(a) halo,
(b) OR^{13},
(c) $N(R^{14})_2$,
(d) C_{1-6}alkyl,
(e) C_{2-6}alkenyl and
(f) C_{3-6}akynyl,

wherein items (d) to (f) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13} and $N(R^{14})_2$;

Y is selected from the group consisting of:

(1) hydrogen,
(2) $-O-R^9$,
(3) $-S(O)_k-R^9$, wherein k is 0, 1 or 2,
(4) $-C-W-R^9$, wherein W is O or $S(O)_k$,
(5) $-N(R^{15})2$,
(6) $-S(O)_k-N(R^{15})_2$,

(7) $-N(R^{15})-S(O)k-N(R^{15})_2$,
(8) NO_2,
(9) $-C(O)-R^{15}$,
(10) $-C(O)O-R^{15}$,
(11) -CN,
(12) halo and
(13) $-O-S(O)_k-R^{15}$,

R^9 is selected from the group consisting of: hydrogen, C_{1-12}alkyl and aryl, wherein C_{1-12}alkyl and aryl are optionally substituted from one up to the maximum number of substituents with halo, or when Y is OR^9 then R^8 and R^9 may be joined together to form a carbonyl group;

each R^{11} and R^{12} is independently selected from the group consisting of:

(1) halo,
(2) C_{1-6}alkyl,
(3) C_{2-6}alkenyl,
(4) C_{1-6}alkoxy and
(5) hydroxy,

wherein items (2) to (4) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{12}, $N(R^{13})_2$ and C_{1-6}alkyl-$S(O)_k$-, wherein k is 0, 1 or 2;

each R^{13} and R^{14} is independently selected from the group consisting of hydrogen and C_{1-4}alkyl, optionally substituted from one up to the maximum number of substitutable positions with halo; and

each R^{15} is independently selected from the group consisting of: hydrogen, C_{1-6}alkyl, aryl and C_{1-12}alkoxycarbonyl, wherein said C_{1-6}alkyl and C_{1-12}alkoxycarbonyl are optionally substituted from one up to the maximum number of substituable positions with halo and said aryl is optionally substituted from one up to

the maximum number of substituable positions with halo and C_{1-4}alkyl, optionally substituted with 1-3 halo groups.

3. The compound according to Claim 2 wherein:

J is NR^1;

K is NR^3;

L is $C(R^5)(R^6)$; and

R^3 and R^5 are joined together to form a double bond.

4. The compound according to Claim 2 wherein the optional double bond shown in ring A of the compound of Formula I is present.

5. The compound according to Claim 2 wherein R^1 is aryl or HET, said aryl or HET optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:

(a) halo,
(b) OR^{13},
(c) $N(R^{14})_2$,
(d) C_{1-6}alkyl,
(e) C_{2-6}alkenyl,
(f) C_{3-6}akynyl,
(g) C_{1-6}alkyl-$S(O)_k$-, wherein k is 0, 1 or 2,
(h) aryl,
(i) aryl-$S(O)_k$-, wherein k is 0, 1 or 2,
(j) HET,
(k) aralkyl,
(l) aroyl,

(m) aryloxy,
(n) aralkoxy and
(o) CN,

wherein items (d) to (g) above and the alkyl portions of item (k) are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13} and $N(R^{14})_2$, and

wherein items (h), (i), (j), (l) and (m) above and the aryl portions of items (k) and (n) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13} and C_{1-4}alkyl.

6. The compound according to Claim 5 wherein R^1 is phenyl, optionally substituted with 1-3 halo groups.

7. The compound according to Claim 2 wherein Y is OR^9.

8. The compound according to Claim 7 wherein R^9 is hydrogen.

9. The compound according to Claim 2 wherein R^7 is methyl.

10. The compound according to Claim 2 wherein R^8 is hydrogen or methyl.

11. The compound according to Claim 2 wherein X is a bond.

12. The compoound according to Claim 2 wherein R^{10} is selected from the group consisting of:
(1) C_{1-6}alkyl,
(2) C_{2-6}alkenyl,
(3) C_{3-6}akynyl,
(4) C_{3-6}cycloalkyl,
(5) C_{1-6}alkoxy,

(6) C_{1-6}alkyl-S(O)$_k$-, wherein k is 0, 1 or 2,

wherein items (1) to (6) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13}, $N(R^{14})_2$, C_{3-6}cycloalkyl and C_{1-6}alkyl-S(O)$_k$, wherein k is 0, 1 or 2.

13. The compound according to Claim 2 wherein R^{10} is selected from the group consisting of:

(1) phenyl
(2) naphthyl,
(3) benzyl,
(4) phenethyl,
(5) phenoxy,
(6) benzoyl and
(7) benzoyloxy,

wherein the aryl portions of items (1) to (7) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:

(a) halo,
(b) OR^{13},
(c) $N(R^{14})_2$,
(d) C_{1-6}alkyl,
(e) C_{2-6}alkenyl,
(f) C_{3-6}akynyl,
(g) C_{1-6}alkyl-S(O)$_k$-, wherein k is 0, 1 or 2,
(h) aryl,
(i) aryl-S(O)$_k$-, wherein k is 0, 1 or 2,
(j) HET,
(k) aralkyl,
(l) aroyl,
(m) aryloxy,
(n) aralkoxy and
(o) CN,

wherein items (d) to (g) above and the alkyl portions of item (k) are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13} and $N(R^{14})_2$, and

wherein items (h), (i), (j), (l) and (m) above and the aryl portions of items (k) and (n) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR^{13} and C_{1-4}alkyl.

14. The compound according to Claim 2 wherein R^{10} is HET or -C_{1-4}alkyl-HET wherein HET is selected from the group consisting of:

(1) pyridine,

(2) thiophene and

(3) furan,

or benzofused analogs of (1) to (3) above.

15. A compound according to Claim 1 of Formula II:



II

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

X is a bond;

R^8 and R^{10} are each independently selected from the group consisting of:

(1) C_{1-6}alkyl, optionally substituted with hydroxy,
(2) C_{2-6}alkenyl,
(3) C_{3-6}akynyl,
(4) C_{3-6}cycloalkyl,
(5) phenyl
(6) naphthyl,
(7) benzyl,
(8) phenethyl and
(9) pyridine, thiophene or furan, or benzofused analogs thereof,

and R^8 is additionally selected from hydrogen,

wherein items (5), (6) and (9) above and aryl portion of items (7) and (8) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:

(a) halo,
(b) hydroxy,
(c) methoxy,
(d) C_{1-4}alkyl,
(e) trifluoromethyl,
(f) phenoxy,
(g) benzyloxy, optionally substituted with methoxy, and
(h) CN;

each R^{11} is independently selected from the group consisting of:
(1) halo,
(2) methyl and
(3) hydroxy; and

R^{14} is independently selected from the group consisting of hydrogen and C_{1-4}alkyl.

16. The compound according to Claim 15 wherein R^8 is selected from the group consisting of hydrogen and C_{1-4}alkyl.

17. A compound according to Claim 1 selected from the group consisting of:




HO
H
N
N
F
HO
H
OCH3
N
N
F
HO
H
N
N
F
HO
H
N
N
F
OCH3
HO
H
N
N
F


HO
OCH3
H
N
N
F
HO
OCH3
OCH3
H
N
N
F
F
HO
H
N
N
F
HO
H
N
N
F
HO
F
H
N
N
F






HO
H
N
N
F
Cl
HO
Cl
H
N
N
F
HO
H
N
N
F
F
F
HO
F
H
N
N
F


O
O
HO
H
N
N
F
HO
H
N
N
F
OCH3
HO
H
N
N
F
F
HO
H
N
N
F




MeO
F
HO
H
N
N
F
N
HO
H
N
N
F
S
HO
H
N
N
F
F
F
HO
H
N
N
F


CF3
HO
H
N
N
F
S
HO
H
N
N
F
HO
H
N
N
F
OMe
F
HO
H
N
N
F


HO
H
N
N
F
HO
H
N
N
F
O
HO
H
N
N
F
F
HO
H
N
N
F


CN
F
HO
H
N
N
F
Cl
F
HO
H
N
N
F
Cl
HO
H
N
N
F


O
O
F
HO
N
N
F
OH
HO
H
N
N
F
OH
HO
H
N
N
F
HO
F
N
N
F
all possible
diastereomers


HO
N
N
F
O
H
N
N
F
HO
H
N
N
F
HO
N
N
F
HO
H
N
N
F


HO
O
H
N
N
F
S
O
H
N
N
F
OH
S
H
N
N
F
all possible
diastereomers
H3C
OH
S
H
N
N
F
all possible
diastereomers


S
H
H3C
H
N
N
F
all possible
diastereomers
O
H
N
N
F
OH
H3C
H
N
N
F
all possible
diastereomers
HO
H
N
N
F


HO
H
N
N
F
F
HO
H
N
N
F
F
HO
H
N
N
F
S
HO
H
N
N
F


HO
S
H
N
N
F
HO
S
H
N
N
F
HO
S
H
N
N
F
HO
H
N
N
F









or a pharmaceutically acceptable salt of any of the above.

18. A compound according to Claim 1 selected from one of the following tables:




OCF3
HO
H
N
N
F
N
F
HO
H
N
N
F
N
F
HO
H
N
N
F
OMe
F
F
HO
H
N
N
F


O
F
F
HO
H
N
N
F
F
HO
H
N
N
F
CF3
F
HO
H
N
N
F
F
HO
H
N
N
F














OH
HO
H
N
N
F

OH
F
HO
H
N
N
F


O
F
HO
H
N
N
F


O
F
HO
H
N
N
F
















F
O
H
N
N
F
F
F
O
H
N
N
F
F
HO
H
N
N
F
F
HO
H
N
N
F










Cl
HO
H
N
N
F
F
HO
H
F
N
N
F
F
HO
H
F
N
N
F
HO
H
N
N
F


HO
H
N
N
F


S
HO
H
N
N
F


S
HO
H
N
N
F


HO
H
N
N
F


HO
H
N
N
F
HO
H
N
N
F
HO
H
N
N
F
N
HO
H
N
N
F






HO
H
N
N
N
F
HO
O
H
N
N
F
HO
O
H
N
N
F
HO
S
H
N
N
F




















OH
O
S
O
H
N
N
F
HO
O
S
O
H
N
N
F
HO
O
S
O
H
N
N
F
HO
O
S
O
H
N
N
F


HO
O
S
O
H
N
N
F


N
N
H
H
N
N
F


S
F
H
N
N
F


S
F
H
N
N
F






HO
H
N
N
F
HO
H
N
N
F
OH
H
N
N
F
OH
H
N
N
F


HO
F
H
N
N
F
HO
F
H
N
N
F


OH
H
N
N
F
OH
H
N
N
F


HO
F
H
N
N
F
HO
F
H
N
N
F
HO
H
N
N
F
HO
H
N
N
F


HO
S
H
N
N
F
HO
S
H
N
N
F
OH
N
H
F
N
N
F
OH
N
H
F
N
N
F


OH
S
H
N
N
F
OH
S
H
N
N
F
OH
S
H
N
N
F
OH
S
H
N
N
F


F
HO
H
N
N
F
N
MeO
H
N
N
F
F
O
H
N
N
F
S=O
O
F
HO
H
N
N
F



or a pharmaceutically acceptable salt of any of the above.

19. A compound according to Claim 1 of Formula III:

5



III

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

n is 0 or 1,

R8 is hydrogen or methyl,

R^9 is hydrogen or methyl or

R^8 and R^9 may be joined together with the oxygen atom shown in Formula III to form a carbonyl group;

R^{10} is selected from the group consisting of:

(1) phenyl,
(2) naphthyl,
(3) pyridyl,
(4) furyl or benzofuryl,
(5) thienyl or benzothienyl, or the S,S-dioxide thereof,
(6) benzyl,
(7) quinoline,
(8) thiazolyl or benzothiazolyl, and
(9) phenylsulfonylmethyl or phenylsulfonylethyl, wherein

groups (1) to (9) are optionally substituted with 1 to 3 substituents independently selected from the group consisting of:

(a) halo,
(b) trifluoromethyl,
(c) trifluoromethoxy,
(d) -N(R^{14}), wherein each R^{14} is indepedently hydrogen or C_{1-4}alkyl,
(e) pyrrolyl,
(f) methoxy, ethoxy or isopropoxy, each optionally substituted with a substituent selected from: methoxy, benzyl, cyclopropylmethyl, cyano, methylthio, methylsulfinyl and methylsulfonyl,
(g) methyl,
(h) vinyl and
(i) hydroxy, and

R^{11} is hydrogen or halo.

20. A compound according to Claim 1 of Formula IV:



IV

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

n is 0 or 1,

R^{10} is selected from the group consisting of:
(1) –CH(OR^{13})-aryl, wherein aryl is phenyl or napthyl,

(2) –CH(OR13)-HET, and

(3) –CH(OR13)-C1-4alkyl or –CH(OR13)-C2-4alkenyl, said –CH(OR13)-C1-4alkyl or –H(OR13)-C2-4alkenyl optionally substituted with phenylsulfonyl,

R13 is hydrogen or methyl,

HET is selected from the group consisting of:

(1) pyridyl,

(2) furyl or benzofuryl,

(3) thienyl or benzothienyl, or the S,S-dioxide thereof,

(4) benzyl,

(5) quinoline,

(6) thiazolyl or benzothiazolyl,

said aryl or HET are optionally substituted with 1 to 3 substituents independently selected from the group consistingof:

(a) halo,

(b) trifluoromethyl,

(c) trifluoromethoxy,

(d) -N(R14), wherein each R14 is indepedently hydrogen or C1-4alkyl,

(e) pyrrolyl,

(f) methoxy, ethoxy or isopropoxy, each optionally substituted with a substituent selected from: methoxy, benzyl, cyclopropylmethyl, cyano, methylthio, methylsulfinyl and methylsulfonyl,

(g) methyl,

(h) vinyl and

(i) hydroxy, and

R11 is hydrogen or halo.

21. A pharmaceutical composition comprising a compound according to Claim 1 in combination with a pharmaceutically acceptable carrier.

22. A method for treating a glucocorticoid receptor mediated disease or condition in a mammalian patient in need of such treatment comprising administering the patient a compound according to Claim 1 in an amount that is effective for treating the glucocorticoid receptor mediated disease or condition.

23. The method according to Claim 22 wherein the glucocorticoid receptor mediated disease or condition is selected from the group consisting of: tissue rejection, leukemias, lymphomas, Cushing's syndrome, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, stroke and spinal cord injury, hypercalcemia, hypergylcemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, Little's syndrome, obesity, metabolic syndrome, inflammatory bowel disease, systemic lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arteritis, rheumatoid arthritis, juvenile rheumatoid arthritis, uveitis, hay fever, allergic rhinitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, organ transplantation, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, discoid lupus erythematosus, inflamed cysts, atopic dermatitis, pyoderma gangrenosum, pemphigus vulgaris, buflous pernphigoid, systemic lupus erythematosus, dermatomyositis, herpes gestationis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type I reactive leprosy, capillary hemangiomas, contact dermatitis, atopic dermatitis, lichen planus, exfoliative dermatitus, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, cutaneous T-cell lymphoma, Human Immunodeficiency Virus (HIV), cell apoptosis, cancer, Kaposi's sarcoma, retinitis pigmentosa, cognitive performance, memory and learning enhancement, depression, addiction, mood disorders, chronic fatigue syndrome, schizophrenia, sleep disorders, and anxiety.

24. A method of selectively modulating the activation, repression, agonism and antagonism effects of the glucocorticoid receptor in a mammal comprising administering to the mammal a compound according to Claim 1 in an amount that is effective to modulate the glucocorticoid receptor.